Categories
Tags
Authors: Davies MA, Morden E, Rosseau P, Arendse J, Bam JL, Cloete K et al. PMID: 36436752 PMCID: PMC9686046 DOI: 10.1016/j.ijid.2022.11.024 Abstract Objectives: We aimed to compare the clinical severity of Omicron BA.4/BA.5 infection with BA.1 and earlier variant infections among laboratory-confirmed SARS-CoV-2 cases in the Western Cape, South Africa, using timing of infection to [...]
Categories: I-CARE Early Covid
Tags:
Authors: Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M PMID: 36195617 PMCID: PMC9531215 DOI: 10.1038/s41467-022-33614-0 Abstract Omicron lineages BA.4 and BA.5 drove a fifth wave of COVID-19 cases in South Africa. Here, we use the presence/absence of the S-gene target as a proxy for SARS-CoV-2 variant/lineage for infections diagnosed using the [...]
Categories: I-CARE Early Covid
Tags:
Authors: Arbel R, Sagy YW, Hoshen M, Battat E, Lavie G, Sergienko R et al. PMID: 36001529 PMCID: PMC9454652 DOI: 10.1056/NEJMoa2204919 Abstract Background: The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-risk, unvaccinated patients infected with the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Data regarding the effectiveness of [...]
Categories: I-CARE Early Covid
Tags: COVID-19, nirmatrelvir, Omicron
Authors:Baxter AL, Schwartz KR, Johnson RW, Srinivasa AS. PMID:36007135 DOI: 10.1177/01455613221123737 Abstract Objective: To determine whether initiating saline nasal irrigation after COVID-19 diagnosis reduces hospitalization and death in high-risk outpatients compared with observational controls, and if irrigant composition impacts severity. Methods: Participants 55 and older were enrolled within 24 hours of a + PCR COVID-19 [...]
Categories: I-CARE Early Covid, I-PREVENT
Tags:
Authors: Wimalawansa SJ. PMID: 35889955 PMCID: PMC9319502 DOI: 10.3390/nu14142997 Abstract Vitamin D deficiency is a global public health problem, a pandemic that commonly affects the elderly and those with comorbidities such as obesity, diabetes, hypertension, respiratory disorders, recurrent infections, immune deficiency, and malignancies, as well as ethnic minorities living in temperate countries. The same groups [...]
Categories: I-CARE Early Covid, I-PREVENT, MATH+
Tags:
Authors: Parvez SA, Saha MK, Araf Y, Islam T, Ohtsuki G PMID: 35759231 PMCID: PMC9210926 DOI: 10.1002/iid3.639 Abstract Introduction: Prominently accountable for the upsurge of COVID-19 cases as the world attempts to recover from the previous two waves, Omicron has further threatened the conventional therapeutic approaches. The lack of extensive research regarding Omicron has raised [...]
Categories: I-CARE Early Covid
Tags:
Authors: Callaway E doi: https://doi.org/10.1038/d41586-022-01730-y Abstract The lineages’ rise seems to stem from their ability to infect people who were immune to earlier forms of Omicron and other variants. Keywords: vaccines, virology, SARS-CoV2 Source: https://www.nature.com/articles/d41586-022-01730-y Archive: https://archive.is/M7EN7
Categories: I-CARE Early Covid
Tags:
Authors: Hachmann NP, Miller J, Collier AY, Ventura JD, Yu J PMID: 35731894 PMCID: PMC9258748 DOI: 10.1056/NEJMc2206576 Abstract In recent months, multiple lineages of the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged,1 with subvariants BA.1 and BA.2 showing substantial escape from neutralizing antibodies.2-5 Subvariant BA.2.12.1 is now the dominant [...]
Categories: I-CARE Early Covid
Tags:
Authors: Muller C, Karl N, Ziebuhr J, Pleschka S PMID: 35805887 PMCID: PMC9266999 doi: 10.3390/ijms23136880 Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the coronavirus disease-19 (COVID-19) is still challenging healthcare systems and societies worldwide. While vaccines are available, therapeutic strategies are developing and need to be adapted to each patient. Many clinical [...]
Categories: I-CARE Early Covid
Tags:
Authors: Gupta K, Strymish J, Stack G, Chamess M DOI: https://doi.org/10.21203/rs.3.rs-1588371/v1 Abstract Initiation of NM/R treatment on Day 0 in a 71-year-old vaccinated and boosted male resulted in rapid resolution of COVID-19 symptoms followed one week later by the development of typical cold symptoms. SARS-CoV-2 viral load fluctuated in parallel with symptoms, with two distinct [...]
Categories: I-CARE Early Covid
Tags: COVID-19, nirmatrelvir, SARS-CoV-2